Repligen Corporation (RGEN)

Market Cap	9.35B
Revenue (ttm)	801.54M
Net Income (ttm)	185.96M
Shares Out	55.56M
EPS (ttm)	3.24
PE Ratio	51.96
Forward PE	56.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	543,926
Open	171.25
Previous Close	169.57
Day's Range	167.73 - 173.84
52-Week Range	137.21 - 262.26
Beta	1.09
Analysts	Buy
Price Target	207.26 (+23.11%)
Earnings Date	Apr 26, 2023

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 1,852
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN

Financial Performance

In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%.

Analyst Forecast

According to 17 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $207.26, which is an increase of 23.11% from the latest price.

Price Target

$207.26

(23.11% upside)

Analyst Consensus: Buy